Regeneron Pharmaceuticals Inc.
said Friday that the U.S. Food and Drug Administration has approved its treatment for CHAPLE disease, a rare and life-threatening hereditary immune disease. The treatment, Veopoz, is the first to be approved for the condition, which can cause the body to attack normal cells and damage blood and lymph vessels in the upper digestive tract. The monoclonal antibody is approved for adults and children one year of age and older with CHAPLE disease, Regeneron said in a release.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: